Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group
Mehmet Kemal Samur, Anil Aktas Samur, Mariateresa Fulciniti, Raphael Szalat, Tessa Han, Masood Shammas, Paul Richardson, Florence Magrangeas, Stephane Minvielle, Jill Corre, Philippe Moreau, Anjan Thakurta, Kenneth C Anderson, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C Munshi, Mehmet Kemal Samur, Anil Aktas Samur, Mariateresa Fulciniti, Raphael Szalat, Tessa Han, Masood Shammas, Paul Richardson, Florence Magrangeas, Stephane Minvielle, Jill Corre, Philippe Moreau, Anjan Thakurta, Kenneth C Anderson, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C Munshi
Abstract
Purpose: Multiple myeloma (MM) is accompanied by heterogeneous somatic alterations. The overall goal of this study was to describe the genomic landscape of myeloma using deep whole-genome sequencing (WGS) and develop a model that identifies patients with long survival.
Methods: We analyzed deep WGS data from 183 newly diagnosed patients with MM treated with lenalidomide, bortezomib, and dexamethasone (RVD) alone or RVD + autologous stem cell transplant (ASCT) in the IFM/DFCI 2009 study (ClinicalTrials.gov identifier: NCT01191060). We integrated genomic markers with clinical data.
Results: We report significant variability in mutational load and processes within MM subgroups. The timeline of observed activation of mutational processes provides the basis for 2 distinct models of acquisition of mutational changes detected at the time of diagnosis of myeloma. Virtually all MM subgroups have activated DNA repair-associated signature as a prominent late mutational process, whereas APOBEC signature targeting C>G is activated in the intermediate phase of disease progression in high-risk MM. Importantly, we identify a genomically defined MM subgroup (17% of newly diagnosed patients) with low DNA damage (low genomic scar score with chromosome 9 gain) and a superior outcome (100% overall survival at 69 months), which was validated in a large independent cohort. This subgroup allowed us to distinguish patients with low- and high-risk hyperdiploid MM and identify patients with prolongation of progression-free survival. Genomic characteristics of this subgroup included lower mutational load with significant contribution from age-related mutations as well as frequent NRAS mutation. Surprisingly, their overall survival was independent of International Staging System and minimal residual disease status.
Conclusion: This is a comprehensive study identifying genomic markers of a good-risk group with prolonged survival. Identification of this patient subgroup will affect future therapeutic algorithms and research planning.
Figures
References
- Manier S, Salem KZ, Park J, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14:100–113.
- Perrot A, Corre J, Avet-Loiseau H. Risk stratification and targets in multiple myeloma: From genomics to the bedside. Am Soc Clin Oncol Educ Book. 2018;38:675–680.
- Robiou du Pont S, Cleynen A, Fontan C, et al. Genomics of multiple myeloma. J Clin Oncol. 2017;35:963–967.
- Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.
- Bolli N, Biancon G, Moarii M, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32:2604–2616.
- Bolli N, Maura F, Minvielle S, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018;9:3363.
- Walker BA, Mavrommatis K, Wardell CP, et al: Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132:587-597, 2018 [Erratum: Blood 132:1461, 2018]
- Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467–472.
- Khurana E, Fu Y, Chakravarty D, et al. Role of non-coding sequence variants in cancer. Nat Rev Genet. 2016;17:93–108.
- Zhang W, Bojorquez-Gomez A, Velez DO, et al. A global transcriptional network connecting noncoding mutations to changes in tumor gene expression. Nat Genet. 2018;50:613–620.
- Gloss BS, Dinger ME. Realizing the significance of noncoding functionality in clinical genomics. Exp Mol Med. 2018;50:97.
- Piraino SW, Furney SJ. Beyond the exome: the role of non-coding somatic mutations in cancer. Ann Oncol. 2016;27:240–248.
- Rahman S, Mansour MR: The role of noncoding mutations in blood cancers. Dis Model Mech 12:dmm041988, 2019.
- Zhu H, Uusküla-Reimand L, Isaev K, et al. Candidate cancer driver mutations in distal regulatory elements and long-range chromatin interaction networks. Mol Cell. 2020;77:1307–1321.e10.
- Hornshøj H, Nielsen MM, Sinnott-Armstrong NA, et al. Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival. NPJ Genom Med. 2018;3:1.
- Corre J, Cleynen A, Robiou du Pont S, et al. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018;32:2636–2647.
- Szalat R, Munshi NC: Genomic heterogeneity in multiple myeloma. Curr Opin Genet Dev 30:56-65, 2015 [Erratum: Curr Opin Genet Dev 37:158, 2016]
- Aktas Samur A, Minvielle S, Shammas M, et al. Deciphering the chronology of copy number alterations in multiple myeloma. Blood Cancer J. 2019;9:39.
- Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–1320.
- Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–219.
- Shen R, Seshan VE. FACETS: Allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44:e131.
- Chen X, Schulz-Trieglaff O, Shaw R, et al. Manta: Rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32:1220–1222.
- McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122.
- Rosales RA, Drummond RD, Valieris R, et al. signeR: An empirical Bayesian approach to mutational signature discovery. Bioinformatics. 2017;33:8–16.
- Sztupinszki Z, Diossy M, Krzystanek M, et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer. 2018;4:16.
- Hoadley KA, Yau C, Hinoue T, et al: Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173:291-304.e6, 2018.
- ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium Pan-cancer analysis of whole genomes. Nature. 2020;578:82–93.
- Gonzalez-Perez A, Sabarinathan R, Lopez-Bigas N. Local determinants of the mutational landscape of the human genome. Cell. 2019;177:101–114.
- Alexandrov LB, Kim J, Haradhvala NJ, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94–101.
- Maura F, Petljak M, Lionetti M, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2018;32:1044–1048.
- Walker BA, Wardell CP, Murison A, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997.
- Hoang PH, Cornish AJ, Dobbins SE, et al. Mutational processes contributing to the development of multiple myeloma. Blood Cancer J. 2019;9:60.
- Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120:1067–1076.
- Affer M, Chesi M, Chen WG, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014;28:1725–1735.
- Maura F, Rustad EH, Yellapantula V, et al. Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. Leukemia. 2020;34:1476–1480.
- Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159–170.
- Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: A report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–2869.
- Barwick BG, Neri P, Bahlis NJ, et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat Commun. 2019;10:1911.
- Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. Blood. 2016;127:2955–2962.
- Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37:1228–1263.
- Perrot A, Lauwers-Cances V, Tournay E, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019;37:1657–1665.
- Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009;27:4585–4590.
- Weinhold N, Kirn D, Seckinger A, et al. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016;101:e116–e119.
- Miller A, Asmann Y, Cattaneo L, et al. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. Blood Cancer J. 2017;7:e612.
- Samur MK, Minvielle S, Gulla A, et al. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018;32:2626–2635.
- Kuiper R, Broyl A, de Knegt Y, et al: A gene expression signature for high-risk multiple myeloma. Leukemia 26:2406-2413, 2012 [Erratum: Leukemia 28:1178-1180, 2014]
- Kumar S, Fonseca R, Ketterling RP, et al: Trisomies in multiple myeloma: Impact on survival in patients with high-risk cytogenetics. Blood 119:2100-2105, 2012 [Erratum: Blood 123:1621, 2014]
Source: PubMed